Viridian Therapeutics, Inc. (VRDN) Misses Q3 EPS by 9c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q3 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $86 thousand versus the consensus estimate of $91 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Trump Did Not Repeat Termination Of Interim Deal With Iran During Nato Summit, Source Familiar With The Talks Says - Reuters
• 60 Degrees Pharma signs option deal with Florida State for tick disease compound
• Innoviz partners with AeroNous to add LiDAR to counter-drone platform